首页 NewLink Genetics(usNLNK)-基本信息

NewLink Genetics(usNLNK)-基本信息

日报更新时间:

周报更新时间:01-16 11:49

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:NewLink Genetics


简介:Newlink Genetics Corporation是一家生物制药公司,专注于发现、开发和商业化免疫治疗产品,改善癌症患者的治疗方案


电话:1-515-2965555


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

NewLink Genetics公司主要从事小分子疫苗产品的制造与销售,产品包括治疗:胰脏癌、急性肺癌及黑色素瘤等免疫制品及药品等。其产品组合包括: 刺激人体免疫系统的基于其超急性免疫治疗技术的生物制品; 小分子候选产品,通过抑制indoleamine-(2,3)-dioxygenase和tryptophan-(2.3)-dioxygenase通路来突破免疫系统耐受癌症; HyperAcute Pancreas免疫疗法(主要候选产品,胰脏癌疫苗),已获美国FDA核准为胰腺癌的孤儿药,并进入III期临床试验阶段(2015.5.11——NewLink公司宣布该公司主打产品胰腺癌疫苗algenpantucel-L的III期数据没有显示进展,股价暴跌近30%,虽然这个药物拿到过Fda的快速批准通道,这个拖了好几年的III期研究就是这个公司用来大跌的利器。); HyperAcute Lung免疫疗法,治疗晚期非小细胞肺癌; HyperAcute Melanoma免疫疗法,治疗晚期黑色素瘤; 肾癌、前列腺癌和乳腺癌免疫疗法; IDO通路抑制剂(包括indoximod和NLG919),用于治疗转移性乳腺癌和转移性前列腺癌;; NLG2101,治疗转移性乳腺癌; NLG2102,治疗难治性恶性脑肿瘤; NLG2103,治疗晚期黑色素瘤; NLG2014,治疗转移性胰腺癌。此外,NewLink Genetics公司还与默克公司合作开发埃博拉病毒疫苗。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-22 Kennedy (Eugene P. M.D.) Officer Sell 359 1.57
2019-01-03 Link (Charles J Jr) Chief Executive Officer Sell 5906 1.55
2019-01-03 Vahanian (Nicholas N) President Sell 2626 1.55
2019-01-03 Kennedy (Eugene P. M.D.) Officer Sell 376 1.55
2019-01-03 Langren Carl W Chief Financial Officer Sell 398 1.55
2019-01-01 Langren Carl W Chief Financial Officer Sell 646 1.66
2019-01-01 Link (Charles J Jr) Chief Executive Officer Sell 5699 1.66
2019-01-01 Vahanian (Nicholas N) President Sell 2229 1.66
2018-12-11 Langren Carl W Chief Financial Officer Buy 2564 0.80
2018-12-11 Link (Charles J Jr) Chief Executive Officer Buy 2564 0.80
2018-09-30 Henneman (John Bell Iii) Officer Sell 2484 2.28
2018-07-09 Talarico (Ernest J III) Director Buy 3571 2.10
2018-07-09 Talarico (Ernest J III) Director Buy 7142 2.10
2018-07-09 Talarico (Ernest J III) Director Sell 13806 4.82
2018-07-09 Talarico (Ernest J III) Director Buy 3093 2.10
2018-01-19 Kennedy (Eugene P. M.D.) Officer Sell 85 8.62
2018-01-03 Wiley (Brian) Officer Sell 603 10.06
2018-01-03 Vahanian (Nicholas N) President Sell 2659 10.06
2018-01-03 Henneman (John Bell Iii) Chief Financial Officer Sell 1323 10.06
2018-01-03 Langren Carl W Officer Sell 257 10.06
2018-01-03 Link (Charles J Jr) Chief Executive Officer Sell 5541 10.06
2018-01-03 Kennedy (Eugene P. M.D.) Officer Sell 409 10.06
2018-01-01 Henneman (John Bell Iii) Chief Financial Officer Sell 164 8.47
2018-01-01 Link (Charles J Jr) Chief Executive Officer Sell 8939 8.47
2018-01-01 Wiley (Brian) Officer Sell 1237 8.47

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Worth Venture Partners, LLC 245649 0.66% 245649 -- 2019-03-31
Northern Trust Investments Inc 520716 1.40% -13511 -2.53% 2019-07-31
State Street Corporation 526561 1.41% 5900 1.13% 2019-03-31
Connor Clark & Lunn Inv Mgmt Ltd 628097 1.68% -5500 -0.87% 2019-03-31
Vanguard Investments Australia Ltd 667212 1.79% -1285 -0.19% 2019-07-31
Panagora Asset Management Inc 671075 1.80% -34246 -4.86% 2019-03-31
Vanguard Group Inc 1082390 2.90% 225171 26.27% 2019-03-31
BlackRock Inc 1815408 4.87% -55719 -2.98% 2019-03-31
Renaissance Technologies Corp 2721813 7.30% 660800 32.06% 2019-03-31
Wells Fargo & Co 501693 1.35% 563 0.11% 2019-03-31
Two Sigma Investments LLC 497319 1.33% 43063 9.48% 2019-03-31
Geode Capital Management, LLC 487981 1.31% -507531 -50.98% 2019-03-31
Dimensional Fund Advisors LP 266656 0.71% -66234 -19.90% 2019-07-31
Vanguard 309233 0.83% -- -- 2019-07-31
Dimensional Fund Advisors, Inc. 316045 0.85% -59821 -15.92% 2019-03-31
Fidelity Management & Research Company 345291 0.93% -7022 -1.99% 2019-07-31
Northern Trust Investments N A 345918 0.93% -2845 -0.82% 2019-03-31
Northern Trust Corp 345918 0.93% -2845 -0.82% 2019-03-31
Acadian Asset Management LLC 404083 1.08% 404083 -- 2019-03-31
Oxford Asset Management, LLC 473761 1.27% -122944 -20.60% 2019-03-31
State Street Global Advisors 296622 0.80% -- -- 2019-06-30
BlackRock Asset Management Canada Ltd 638499 1.71% -42 -0.01% 2019-05-31
BlackRock Fund Advisors 884264 2.37% -400899 -31.19% 2019-05-31
Anson Funds Management LP 282262 0.76% 282262 -- 2018-12-31
J.P. Morgan Investment Management, Inc. 477901 1.28% 26291 5.82% 2018-09-30
J.P. Morgan Securities Inc 662153 1.78% 662153 -- 2018-09-30
JPMorgan Chase & Co 1156871 3.10% 691651 148.67% 2018-09-30
BlackRock Institutional Trust Company NA 716267 1.92% -19564 -2.66% 2018-06-30
Fidelity SelectCo, LLC 658646 1.77% 14 -- 2018-11-30
Wells Fargo Advisors, LLC 514126 1.38% 5550 1.09% 2018-09-30
Alambic Investment Management, L.P. 366995 0.99% 314095 593.75% 2018-06-30
Columbia Mgmt Investment Advisers, LLC 321746 0.86% -- -- 2018-11-30
UBS Asset Mgmt Americas Inc 439967 1.18% 427637 3468.26% 2018-03-31
Baker Bros Advisors LP 507273 1.36% -- -- 2018-06-30
Fidelity Management and Research Company 650756 1.75% -- -- 2018-03-31
T. Rowe Price Associates, Inc. 759607 2.04% -649597 -46.10% 2018-06-30
Redmile Group, LLC 1611746 4.33% -442454 -21.54% 2018-06-30
FMR Inc 650756 1.75% -- -- 2018-03-31
Stine Seed Farm, Inc. 7857732 21.25% 780487 11.03% 2017-10-06
Arnhold & S. Bleichroeder Advisers, LLC 759250 2.04% -1587050 -67.64% 2018-06-30
State Street Corp 473743 1.27% -21754 -4.39% 2018-06-30
J.P. Morgan Investment Management Inc 451610 1.21% -28512 -5.94% 2018-06-30
Candriam Luxembourg 293000 0.79% -- -- 2018-06-30
Tekla Capital Management LLC 205026 0.55% -- -- 2018-06-30
Segall Bryant & Hamill 110624 0.30% -3378 -2.96% 2018-03-31
Merrill Lynch & Co Inc 234580 0.63% 203939 665.58% 2018-03-31
Deutsche Bank AG 226307 0.61% 132358 140.88% 2018-03-31
Alyeska Investment Group, L.P. 247765 0.67% -2233 -0.89% 2018-03-31
Great Point Partners LLC 233500 0.63% -1753599 -88.25% 2018-03-31
Columbia Mangmt Investment Advisers, LLC 309282 0.83% -1293 -0.42% 2017-12-31
Perceptive Advisors LLC 450000 1.21% -- -- 2017-12-31
venBio Select Advisor LLC 795412 2.14% 795412 -- 2017-12-31
Millennium Management LLC 2347359 6.33% 1048752 80.76% 2017-12-31
Pioneer Investment Mgmt Inc 202200 0.54% 202200 -- 2017-12-31
PDT Partners, LLC 349981 1.12% 234186 202.24% 2017-09-30
Marshall Wace North America LP 387627 1.22% 387627 -- 2017-09-30
Orbimed Advisors, LLC 831274 2.65% -1014726 -54.97% 2017-09-30
Orbimed Capital LLC 1251400 4.29% 1251400 -- 2016-12-31
Columbus Circle Investors 485848 1.55% -105917 -17.90% 2017-09-30
Franklin Advisers Inc 515761 1.77% -- -- 2016-09-30
HAP Trading, LLC 297931 1.02% 70203 30.83% 2016-09-30
Close Finsbury Asset Management Limited 309900 1.06% 14300 4.84% 2016-10-31
Americo Financial Life and Annuity Ins 100000 0.35% -- -- 2015-12-31
Bogle Investment Management L P 219571 0.75% -240575 -52.28% 2016-09-30
Susquehanna Financial Group, LLLP 216931 0.75% -98526 -31.23% 2016-09-30
Teachers Advisors Inc 196307 0.67% -- -- 2016-09-30
QS Investors LLC 183473 0.63% 2639 1.46% 2016-09-30
Zurcher Kantonalbank 164312 0.56% 1181 0.72% 2016-09-30
BlackRock Inc. 1575833 3.00% 78224350 0.10% 1999-11-30
Charles J. Link, Jr., M.D. 2006994 3.00% 99627182 0.10% 1999-11-30
FMR, LLC 2363346 3.00% 117316495 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT R2000 Index Fund - NL 109144 0.29% 3707 3.52% 2019-06-30
Vanguard Total Stock Market Index Fund 667212 1.79% -- -- 2019-06-30
Vanguard Extended Market Index Fund 382170 1.02% -- -- 2019-06-30
Vanguard VIF Small Co Gr Portfolio 302850 0.81% -- -- 2019-03-31
DFA US Micro Cap Portfolio 192392 0.52% -- -- 2019-05-31
State Street Russell Small Cap 142484 0.38% -- -- 2019-06-30
Invesco FTSE RAFI US 1500 Small-Mid ETF 114209 0.31% -- -- 2019-07-31
NT R2000 Value Index Fund - Non-Lending 106439 0.29% -- -- 2019-06-30
QS US Small Capitalization Equity CIF 92114 0.25% -- -- 2019-06-30
Northern Trust Russell 2000 Index DC NL 82859 0.22% 1752 2.16% 2019-06-30
iShares Micro-Cap ETF 79140 0.21% -- -- 2019-07-30
NT R2000 Value Index Fund - Lending 77959 0.21% 7455 10.57% 2019-06-30
State Street Russell Small/Mid Cap 63129 0.17% -53300 -45.78% 2019-06-30
Fidelity 50052 0.13% -8237 -14.13% 2019-03-31
BlackRock Extended Equity Market 48014 0.13% -66 -0.14% 2019-06-30
EQ/2000 Managed Volatility Portfolio 46524 0.12% -- -- 2019-05-31
CREF Stock Account 41798 0.11% -- -- 2019-05-31
BlackRock Russell 2000 48244 0.13% 793 1.67% 2019-03-31
Schwab Small Cap Index Fund 62762 0.17% -- -- 2019-05-31
Schwab US Small-Cap ETF 85565 0.23% -- -- 2018-09-21
iShares Russell 2000 Value ETF 226881 0.61% -936 -0.41% 2019-05-31
iShares Russell 2000 ETF 562162 1.51% -5300 -0.93% 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 567462 1.52% -954 -0.17% 2019-05-30
JPMorgan US Small Company Fund 110100 0.30% -265300 -70.67% 2019-03-31
BSF Americas Diversified Eq Abs Ret Fd 73488 0.20% 73488 -- 2018-12-31
Russell 2000 Index Non-Lendable Fund E 65818 0.18% 853 1.31% 2019-03-31
AXA 2000 Managed Volatility Portfolio 46524 0.12% -- -- 2019-01-31
Loncar Cancer Immunotherapy ETF 67651 0.18% -167072 -71.18% 2018-06-20
Virtus LifeSci Biotech Clinical Trls ETF 114912 0.31% 22330 24.12% 2018-06-15
Vanguard Russell 2000 Index Fund 46328 0.12% -528 -1.13% 2019-01-31
DFA US Targeted Value Portfolio 40762 0.11% -- -- 2019-01-31
Bogle Investment Management Sm Cp Gr Fd 35740 0.10% -- -- 2019-01-31
DFA Tax-Managed US Targeted Value Port 59821 0.16% -- -- 2018-12-31
Tekla Life Sciences Investors 63211 0.17% -- -- 2018-09-30
Tekla Healthcare Investors 141815 0.38% -- -- 2018-09-30
Bridgeway Ultra Small Company Market Fd 100000 0.27% -- -- 2018-09-30
Candriam Eqs L Biotechnology 248000 0.67% -- -- 2018-10-31
iShares Nasdaq Biotechnology ETF 398304 1.07% -780 -0.20% 2018-11-30
AXA Rosenberg Global Small Cap Alpha Fd 58500 0.16% -34900 -37.37% 2018-10-31
DWS Biotech 104894 0.28% 34894 49.85% 2018-03-31
Fidelity Advisor 114392 0.31% -- -- 2018-03-31
Columbia VP US Equities Fund 142700 0.38% -- -- 2018-02-28
Rhenman Healthcare Eq L/S 181047 0.49% -- -- 2018-03-31
T. Rowe Price Small-Cap Value Fund 628000 1.69% -203900 -24.51% 2018-06-30
Columbia Small Cap Growth Fund I 93800 0.25% -- -- 2018-01-31
CPR Invest Global Disruptive Opps 151100 0.41% 19000 14.38% 2017-12-31
T. Rowe Price Small-Cap Value 628000 1.69% -203900 -24.51% 2018-06-30
Vanguard Total Stock Mkt Idx 715224 1.92% 28591 4.16% 2018-07-31
JPMorgan US Small Company Instl 414500 1.11% 8100 1.99% 2018-07-31
Vanguard Extended Market Idx Inv 381345 1.03% -- -- 2018-07-31
iShares Nasdaq Biotechnology 410568 0.96% -783 -0.19% 2018-09-12
Vanguard VIF Small Co Gr 195928 0.53% 195928 -- 2018-06-30
iShares Russell 2000 Value 240453 0.56% -- -- 2018-09-12
State Street Russell Small/Mid Cap Idx Fd Cl I 73021 0.25% 4100 5.95% 2017-06-30
Bridgeway Ultra-Small Company Market 100000 0.27% -- -- 2018-06-30
iShares Micro-Cap 77805 0.18% -- -- 2018-09-12
BlackRock Russell 2500 46826 0.13% 92 0.20% 2018-06-30
BlackRock Extended Equity Market K 47687 0.13% 19858 71.36% 2018-06-30
Vanguard Health Care ETF 64455 0.17% 558 0.87% 2018-07-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 70341 0.19% -462 -0.65% 2018-07-31
Fidelity Spartan 58735 0.16% 1827 3.21% 2018-04-30
Russell Small Cap Fund Class B 91495 0.25% 91495 -- 2018-07-31
AXA 2000 Managed Volatility K 46524 0.13% -- -- 2018-06-30
Schwab Small Cap Index 48700 0.13% -400 -0.81% 2018-06-30
CREF Stock R1 129745 0.35% -- -- 2018-04-30
The Vanguard Russell 2000 Growth Index 46228 0.12% -- -- 2018-05-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 42639 0.11% -- -- 2018-05-31
iShares Russell 2000 Growth 288435 0.76% 498 0.17% 2018-06-21
BioShares 92582 0.25% -- -- 2018-06-14
Columbia Small Cap Growth I Z 93800 0.25% -- -- 2018-01-31
Columbia VP US Equities 2 142700 0.38% -- -- 2018-02-28
American Century Small Company Inv 50528 0.14% -- -- 2017-12-31
QS Batterymarch US Sm Cap Eq I 109404 0.35% -- -- 2017-09-30
Franklin Biotechnology Discovery A 205300 0.70% -- -- 2016-12-31
TIAA-CREF Small-Cap Equity Instl 165700 0.57% 5500 3.43% 2016-12-31
Federated MDT Small Cap Growth A 50629 0.17% -12313 -19.56% 2016-09-30
LVIP SSgA Small/Mid Cap 200 Svc 64797 0.22% 1404 2.21% 2016-12-31
BlackRock Small Cap Growth Eq Instl 44190 0.15% 22535 104.06% 2016-12-31
Gotham Absolute Return Fund 569198 2.00% 569198 -- 2015-04-30
SPDR® S&P Biotech ETF 463935 1.50% 3028 0.70% 2015-11-19
Franklin Biotechnology Discovery 350061 1.20% -- -- 2015-07-31
iShares Russell 2000 (AU) 330822 1.10% -420 -0.10% 2015-11-19
Vanguard Strategic Equity Fund 262900 0.90% 71400 37.30% 2015-09-30
Fidelity Advisor® Biotechnology Fund 252479 0.90% -- -- 2015-09-30
Gotham Enhanced Return Fund 246810 0.90% 246810 -- 2015-04-30
Franklin Biotechnology Discovery Fund 205300 0.70% -25700 -11.10% 2015-09-30
UBS (Lux) EF Biotech (USD) 200000 0.70% -- -- 2015-07-31
Fidelity® Select Biotechnology Portfolio 1456947 5.10% -- -- 2015-09-30
iShares US Pharmaceuticals 187848 0.60% -- -- 2015-11-19

Paolo Pucci Presently, Paolo Pucci is Chief Executive Officer & Director at ArQule, Inc. Mr. Pucci is also on the board of West Pharmaceutical Services, Inc. and NewLink Genetics Corp. He previously occupied the position of Senior VP-Global Specialty Medicine Business Unit at Bayer AG President-US Pharmaceutical Operations at Bayer Pharmaceuticals Corp. and Senior Vice President at Bayer Pharma AG (both are subsidiaries of Bayer AG) and Managing Director at Eli Lilly Sweden AB. Mr. Pucci received an undergraduate degree from Universit�0�1�0�2 degli Studi di Napoli Federico II and an MBA from The University of Chicago Booth School of Business.
John B. Henneman Presently, John B. Henneman holds the position of Chief Administrative Officer at NewLink Genetics Corp. Mr. Henneman is also on the board of Alafair Biosciences, Inc., SeaSpine Holdings Corp. and R1 RCM, Inc. In his past career Mr. Henneman occupied the position of Interim Co-Chief Executive Officer & Secretary at Neuromedical Systems, Inc. and Chief Administrative Officer & Vice President at Integra LifeSciences Holdings Corp. and Chairman for Newdeal SAS (a subsidiary of Integra LifeSciences Holdings Corp.). Mr. Henneman received an undergraduate degree from Princeton University and a graduate degree from The University of Michigan Law School.
Paul R. Edick Mr. Paul R. Edick is a President, Chief Executive Officer & Director at Xeris Pharmaceuticals, Inc., an Independent Director at Sucampo Pharmaceuticals, Inc., a Chairman at Iterum Therapeutics Ltd., an Independent Director at PDL BioPharma, Inc., an Independent Director at Neos Therapeutics, Inc., an Independent Director at NewLink Genetics Corp., a Managing Partner at 3G Advisors LLC and a President at Vicuron Pharmaceuticals, Inc. He is on the Board of Directors at Xeris Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., PDL BioPharma, Inc., Neos Therapeutics, Inc. and NewLink Genetics Corp. Mr. Edick was previously employed as an Independent Non-Executive Director by Circassia Ltd., an Independent Non-Executive Director by Circassia Pharmaceuticals Plc, a President, Chief Executive Officer & Director by Durata Therapeutics, Inc., a Chairman by LifeCycle Pharma A/S, a Chief Executive Officer by GANIC Pharmaceuticals, Inc., a Chairman by Life Cycle Pharma A/S, a Chief Executive Officer by MedPointe Healthcare, Inc., a President & Chief Executive Officer by MedPointe, Inc., a President-Asia Pacific & Latin America by Pharmacia Corp., a President-Asia Pacific, Canada & Latin America by G.D. Searle & Co., Inc., a Principal by Baxter Healthcare Corp., a Sales Representative by Procter & Gamble Co., and a President by MedPointe Capital Partners LLC. He also served on the board at Amerita, Inc. and Informed Medical Communications, Inc. He received his undergraduate degree from Hamilton College (New York).
Lisa V. DeLuca Currently, Lisa V. DeLuca occupies the position of Vice President-Regulatory Affairs of NewLink Genetics Corp. and Vice President-Regulatory Affairs for Celator Pharmaceuticals, Inc. She previously held the position of Principal at The Upjohn Co., Principal at Wyeth Corp., Vice President-Global Regulatory Affairs at Eximias Pharmaceutical Corp., VP-Regulatory Affairs & Quality Assurance at Topaz Pharmaceuticals, Inc., Director-Regulatory Affairs at AstraZeneca Pharmaceuticals LP, Vice President-Global Regulatory Affairs at YM Biosciences USA, Inc. and Manager-Regulatory Affairs at Centocor, Inc. Lisa V. DeLuca received a doctorate from the University of Toledo (Ohio) and a graduate degree and an undergraduate degree from Eastern Michigan University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐